- Home
- GILD
GILD
Gilead Sciences Inc.
as 11-18-2024 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 110.9B | IPO Year: | 1992 |
| Target Price: | $93.91 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.10 | EPS Growth: | -97.92 |
| 52 Week Low/High: | $62.07 - $98.90 | Next Earning Date: | 11-06-2024 |
| Revenue: | $28,299,000,000 | Revenue Growth: | 3.31% |
| Revenue Growth (this year): | 5.71% | Revenue Growth (next year): | 0.37% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parsey Merdad | GILD | Chief Medical Officer | Nov 6 '24 | Sell | $91.50 | 25,590 | $2,341,485.00 | 99,599 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Nov 6 '24 | Sell | $91.28 | 5,000 | $456,400.00 | 73,127 | |
| Parsey Merdad | GILD | Chief Medical Officer | Oct 1 '24 | Sell | $83.83 | 2,000 | $167,660.00 | 99,599 | |
| Parsey Merdad | GILD | Chief Medical Officer | Sep 12 '24 | Sell | $84.50 | 21,246 | $1,795,287.00 | 99,599 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Sep 12 '24 | Sell | $83.74 | 29,357 | $2,459,576.75 | 73,127 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Aug 28 '24 | Sell | $78.03 | 9,513 | $742,299.39 | 73,127 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
MT Newswires
19 hours ago
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
MT Newswires
19 hours ago
RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81
Clinical Trials Arena
20 hours ago
Gilead’s Livdelzi shows promise in PBC clinical trial
Morningstar Research
a day ago
Analyst Report: Gilead Sciences, Inc.
Benzinga
4 days ago
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
MT Newswires
4 days ago
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
Business Wire
4 days ago
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
MT Newswires
4 days ago
Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.